Skip to Content

Galeterone Approval Status

  • FDA approved: No
  • Generic name: galeterone
  • Company: Tokai Pharmaceuticals, Inc.
  • Treatment for: Prostate Cancer

Galeterone (TOK-001) is an androgen receptor antagonist and CYP17 lyase inhibitor in development for the treatment of metastatic castration-resistant prostate cancer (CRPC).

Development Status and FDA Approval Process for galeterone

DateArticle
Jun 12, 2012Tokai Pharmaceuticals' Galeterone Receives Fast Track Designation from the FDA for the Treatment of Advanced Prostate Cancer

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide